163 related articles for article (PubMed ID: 28778563)
1. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.
Men P; He N; Song C; Zhai S
Diabetes Metab; 2017 Dec; 43(6):493-500. PubMed ID: 28778563
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
[TBL] [Abstract][Full Text] [Related]
3. Use of dipeptidyl peptidase-4 inhibitors and the risk of arthralgia: Population-based cohort and nested case-control studies.
Wang CY; Fu SH; Yang RS; Hsiao FY
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):500-506. PubMed ID: 30724413
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.
Mascolo A; Rafaniello C; Sportiello L; Sessa M; Cimmaruta D; Rossi F; Capuano A
Drug Saf; 2016 May; 39(5):401-7. PubMed ID: 26873369
[TBL] [Abstract][Full Text] [Related]
5. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
Rehman MB; Tudrej BV; Soustre J; Buisson M; Archambault P; Pouchain D; Vaillant-Roussel H; Gueyffier F; Faillie JL; Perault-Pochat MC; Cornu C; Boussageon R
Diabetes Metab; 2017 Feb; 43(1):48-58. PubMed ID: 27745828
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
Kaneko M; Narukawa M
Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
[TBL] [Abstract][Full Text] [Related]
8. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
Li R; Wang R; Li H; Sun S; Zou M; Cheng G
Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.
Wu S; Hopper I; Skiba M; Krum H
Cardiovasc Ther; 2014 Aug; 32(4):147-58. PubMed ID: 24750644
[TBL] [Abstract][Full Text] [Related]
11. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials.
Kongwatcharapong J; Dilokthornsakul P; Nathisuwan S; Phrommintikul A; Chaiyakunapruk N
Int J Cardiol; 2016 May; 211():88-95. PubMed ID: 26991555
[TBL] [Abstract][Full Text] [Related]
12. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.
Lyu X; Zhu X; Zhao B; Du L; Chen D; Wang C; Liu G; Ran X
Sci Rep; 2017 Mar; 7():44865. PubMed ID: 28322294
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis.
Liu D; Jin B; Chen W; Yun P
BMC Pharmacol Toxicol; 2019 Mar; 20(1):15. PubMed ID: 30832701
[TBL] [Abstract][Full Text] [Related]
14. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
Chen M; Liu Y; Jin J; He Q
Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing.
Schott G; Martinez YV; Ediriweera de Silva RE; Renom-Guiteras A; Vögele A; Reeves D; Kunnamo I; Marttila-Vaara M; Sönnichsen A
BMC Geriatr; 2017 Oct; 17(Suppl 1):226. PubMed ID: 29047372
[TBL] [Abstract][Full Text] [Related]
18. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: A network meta-analysis of randomized controlled trials.
Yang J; Huang C; Wu S; Xu Y; Cai T; Chai S; Yang Z; Sun F; Zhan S
PLoS One; 2017; 12(12):e0187537. PubMed ID: 29206832
[TBL] [Abstract][Full Text] [Related]
19. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Guo WQ; Li L; Su Q; Dai WR; Ye ZL
Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials.
Fu J; Zhu J; Hao Y; Guo C; Zhou Z
Sci Rep; 2016 Jul; 6():29104. PubMed ID: 27384445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
